AstraZeneca is stepping up its pitch for a slice of the cell therapy space, paying $200 million upfront for a solid tumor player that recently hustled an autologous, fully individualized, multispecific prospect into the clinic. The biotech, Neogene Therapeutics, is part of a clutch of companies that see T-cell receptor therapies (TCR-Ts) as the key to expanding the modality into solid tumors. Source: Fierce Biotech 29/11/2022